List of Excipients in API cabozantinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing cabozantinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | ANHYDROUS LACTOSE | 2032-02-10 |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | CELLULOSE, MICROCRYSTALLINE | 2032-02-10 |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | CROSCARMELLOSE SODIUM | 2032-02-10 |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | FERRIC OXIDE YELLOW | 2032-02-10 |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | HYDROXYPROPYL CELLULOSE | 2032-02-10 |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | HYPROMELLOSES | 2032-02-10 |
| Exelixis Inc | CABOMETYX | cabozantinib | 42388-023 | MAGNESIUM STEARATE | 2032-02-10 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for cabozantinib
Excipient focus: ANHYDROUS LACTOSE
cabozantinib drug variants containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
cabozantinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
cabozantinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
cabozantinib drug variants containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
cabozantinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
cabozantinib drug variants containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
cabozantinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
cabozantinib drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
cabozantinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRIACETIN
cabozantinib drug variants containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| Exelixis Inc | cabozantinib | 42388-023 |
| >Company | >Ingredient | >NDC |
cabozantinib drug variants not containing TRIACETIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
